---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-26-000059"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2026-08-06T12:03:06+00:00"
generated_at: "2026-08-06T12:05:41.167526+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q2 2026 revenue up 19% to $83.2M; net income $37.4M, EPS $0.28

## Summary
- Total revenue $83.2M (+19% YoY); LUPKYNIS net product sales $79.4M (+19% YoY).
- Net income $37.4M (+74% YoY); diluted EPS $0.28 (+75% YoY).
- Cash from operations $52.5M; cash position $443.1M at June 30, 2026.
- Reiterated 2026 total revenue guidance $315M-$325M (11-15% growth).
- Initiated PRESERVE Phase 4 study combining LUPKYNIS with biologics; aritinercept in four indications.

## SEC filing metadata
- accession: 0001600620-26-000059
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2026-08-06T12:03:06+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/0001600620-26-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/auph-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-26-000059
- JSON: https://secwatch.observer/filing/0001600620-26-000059.json
- Plain text: https://secwatch.observer/filing/0001600620-26-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.